Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
Aclaris Therapeutics announced positive full top line results from a first‑in‑human Phase 1a trial of ATI‑052, a bispecific antibody targeting TSLP and IL‑4Rα. The study in healthy volunteers tested single doses up to 720 mg and multiple weekly doses up to 480 mg and showed a favorable safety, pharmacokinetic, and pharmacodynamic profile with an estimated half‑life of about 45 days, supporting the potential for dosing as infrequently as every three months.
The company is enrolling Phase 1b proof‑of‑concept trials of ATI‑052 in asthma and atopic dermatitis, with top line data planned for the second half of 2026 and a Phase 2b asthma program expected to start in the fourth quarter of 2026. Aclaris also selected lichen planus (LP) as the lead indication for its oral ITK/JAK3 inhibitor ATI‑2138 and plans a multi‑part Phase 2b basket trial in LP subtypes beginning in the second half of 2026, citing a potential U.S. market opportunity above $1.0 billion and up to $4.0 billion.
Aclaris Therapeutics, Inc. insider-related entity executes open-market sale. On behalf of BML Investment Partners, L.P., a fund associated with ten percent owner Michael Leonard, 300,000 shares of Aclaris common stock were sold in an open-market transaction at $4.53 per share. Following this sale, the fund’s indirect holdings reported as beneficially owned by Mr. Leonard totaled 13,950,000 shares, which he reports with a disclaimer of beneficial ownership except to the extent of his pecuniary interest.
BML Investment Partners, L.P. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 13,950,000 shares of Aclaris Therapeutics common stock, representing 9.9% of the class based on 139,663,680 shares outstanding as disclosed on a DEF 14A dated 4/23/2026. The filing states shared voting and dispositive power over these shares and includes a signature block explaining indirect ownership through BML Capital Management, LLC and Braden M. Leonard, with a disclaimer that the reporting persons do not constitute a statutory group under Rule 13d-5(b)(1).
Aclaris Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 14, 2026, holding 139,663,680 shares of common stock, may vote online using a 16-digit control number.
Three items are up for vote: electing two directors (Anand Mehra and Maxine Gowen) for terms ending in 2029, an advisory “say-on-pay” vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. The board is classified into three classes and currently has eight members, six of whom are independent under Nasdaq rules.
The proxy details 2025 pay for named executive officers, including total compensation of $3,375,591 for CEO Neal Walker, $1,490,790 for CFO Kevin Balthaser, and $1,447,106 for Chief Business Officer James Loerop, combining salary, stock awards, options and bonuses. It also discloses major shareholders such as BML Investment Partners at 10.2% and Biosion, Inc. at 8.1%, outlines board committee responsibilities, insider trading and clawback policies, and explains how votes, broker non-votes and quorum (69,831,841 shares) are determined.
Aclaris Therapeutics ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial interests in 7,626,705 shares of Aclaris common stock, representing 6.3% of the class based on 120,595,189 shares outstanding as of January 30, 2026. The filing states the Fund directly holds the 7,626,705 shares; RA Capital serves as investment adviser with shared voting and dispositive power over those shares. The Reporting Persons disclaim status as a group and include a statement that the Fund has delegated voting and disposition authority with a 61-day notice constraint.
Aclaris Therapeutics Inc receives an amended beneficial ownership filing from The Vanguard Group reporting 0 shares of Common Stock and 0% ownership in this amendment. The filing notes an internal realignment at Vanguard on January 12, 2026 that led certain subsidiaries and divisions to report separately under SEC Release No. 34-39538.
The filing is administrative: it states Vanguard and its covered accounts hold no beneficial shares of Aclaris Common Stock as reported and documents the change in reporting allocation among Vanguard entities. The signature block records filing execution by Ashley Grim, Head of Global Fund Administration.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 9,345,000 shares of Aclaris Therapeutics common stock, representing 7.01% of the class as of March 16, 2026. The filing states the holders have shared voting and dispositive power over 9,345,000 shares and zero sole voting or dispositive power.
The filing explains the percent is calculated using 133,295,189 shares, derived from 120,595,189 shares outstanding as of January 30, 2026 plus 12.7 million shares sold under a sales agreement from March 2, 2026 through March 9, 2026. The report is a joint Schedule 13G filing under Rule 13d-1(k) and lists Deep Track Capital, LP as the relevant entity for control purposes.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.
Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.